John G McHutchison

John G McHutchison

UNVERIFIED PROFILE

Are you John G McHutchison?   Register this Author

Register author
John G McHutchison

John G McHutchison

Publications by authors named "John G McHutchison"

Are you John G McHutchison?   Register this Author

100Publications

5549Reads

11Profile Views

Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.

Liver Int 2018 10 22;38(10):1849-1859. Epub 2018 Feb 22.

Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.13706DOI Listing
October 2018

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.

Gastroenterology 2018 03 22;154(4):989-997. Epub 2017 Nov 22.

Graduate Institute of Clinical Medicine, Hepatitis Research Center and Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00165085173636
Publisher Site
http://dx.doi.org/10.1053/j.gastro.2017.11.011DOI Listing
March 2018

Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.

Antivir Ther 2016 1;21(7):605-609. Epub 2016 Jul 1.

Gilead Sciences, Inc., Foster City, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3066DOI Listing
February 2018

Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.

Antivir Ther 2016 27;21(8):679-687. Epub 2016 Jun 27.

Texas Liver Institute and the University of Texas Health Science Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3062DOI Listing
February 2018

The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease.

Antivir Ther 2016 6;21(3):185-94. Epub 2015 Oct 6.

Liver Center, Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP2997DOI Listing
January 2018

On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.

Antivir Ther 2016 18;21(6):541-546. Epub 2016 Feb 18.

Department of Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3851/IMP3037DOI Listing
January 2018

Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.

Clin Infect Dis 2017 Sep;65(5):864-866

Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/cid/cix441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248462PMC
September 2017

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.

N Engl J Med 2017 06;376(22):2134-2146

From Hospital Saint Joseph, Marseille (M.B.), and University Hospital of Bordeaux, Pessac (V.L.) - both in France; Henry Ford Health System, Detroit (S.C.G.); Northwestern University, Chicago (S.L.F.); Ottawa Hospital Research Institute, Ottawa (C.L.C.), and St. Paul's Hospital, Vancouver, BC (A.R.) - both in Canada; Huntington Medical Research Institutes, Pasadena (M.T.), Cedars-Sinai Medical Center, Los Angeles (T.T.T.), and Gilead Sciences, Foster City (R.H.H., L.M.S., H.D.-S., E.S., J.Z., K.C.H., G.M.S., D.M.B., J.G.M.) - all in California; Digestive Disease Associates, Catonsville, MD (N.R.); Baylor College of Medicine, Houston (J.M.V.); Monash Health and Monash University, Clayton, VIC (S.P.), and Royal Prince Alfred Hospital, Sydney (S.I.S.) - both in Australia; Icahn School of Medicine at Mount Sinai (M.B.B.) and Columbia University Medical Center (E.C.V.) - both in New York; ifi-Institute for Interdisciplinary Medicine, Hamburg (P.B.), Hannover Medical School, Hannover (M.P.M.), and Johann Wolfgang Goethe University Medical Center, Frankfurt (S.Z.) - all in Germany; University of Washington (C.S.L.) and Swedish Medical Center (K.V.K.) - both in Seattle; Gastro One, Germantown, TN (Z.H.Y.); Beth Israel Deaconess Medical Center, Boston (M.P.C.); University of Miami, Miami (E.R.S.); and University of Pennsylvania, Philadelphia (K.R.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613512DOI Listing
June 2017

Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.

Gastroenterology 2017 05 27;152(6):1366-1371. Epub 2017 Jan 27.

Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2017.01.017DOI Listing
May 2017

Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.

Ann Intern Med 2017 Jan 15;166(2):109-117. Epub 2016 Nov 15.

From Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Gilead Sciences, Foster City, California; Hôpital Saint Joseph, Marseilles, and Hôpital Cochin, Paris, France; Medical University of Vienna, Vienna, Austria; and Hannover Medical School, Hannover, Germany.

View Article

Download full-text PDF

Source
http://annals.org/article.aspx?doi=10.7326/M16-1205
Publisher Site
http://dx.doi.org/10.7326/M16-1205DOI Listing
January 2017

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

N Engl J Med 2015 Dec 16;373(27):2618-28. Epub 2015 Nov 16.

From the Beth Israel Deaconess Medical Center, Boston (M.P.C.); Baylor University Medical Center, Dallas (J.G.O.), and Texas Liver Institute, University of Texas Health Science Center, San Antonio (E.L.) - both in Texas; Ochsner Medical Center, New Orleans (N.B.); Duke University, Durham (A.J.M.), and School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (M.F.) - both in North Carolina; Washington University School of Medicine, St. Louis (K.M.K.); Thomas Jefferson University (J.M.F.) and University of Pennsylvania School of Medicine (K.R.R.) - both in Philadelphia; Northwestern University, Chicago (S.L.F.); Mount Sinai Hospital (T.S.), New York University School of Medicine (L.T.), and Weill Cornell Medical College (R.S.B.) - all in New York; University of Michigan, Ann Arbor (R.F.); University of Miami, Miami (E.S.); Gilead Sciences, Foster City, CA (B.D., D.A., J.M., A.O., D.M.B., J.G.M.); and Intermountain Medical Center, Salt Lake City (M.C.).

View Article

Download full-text PDF

Source
http://www.natap.org/2015/AASLD/nejmoa1512610(1).pdf
Web Search
http://www.idchula.org/wp-content/uploads/2015/12/nejmoa1512
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1512614
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1512614DOI Listing
December 2015

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

N Engl J Med 2015 Dec 16;373(27):2599-607. Epub 2015 Nov 16.

From the Toronto Centre for Liver Disease, Toronto (J.J.F.), University of British Columbia, Vancouver (E.Y.), and University of Alberta, Edmonton (S.D.S.) - all in Canada; Weill Cornell Medical College, New York (I.M.J.); Université Paris-Est, Créteil (C.H.), Service d'Hépatologie, Hôpital Beaujon, INSERM UMR 1149, Université Paris Diderot, Clichy (T.A.), and Université d'Auvergne, Clermont Ferrand (A.A.) - all in France; Ruane Medical and Liver Health Institute (P.J.R.), Kaiser Permanente Los Angeles Medical Center (W.J.T.), Cedars-Sinai Medical Center (T.T.T.), Los Angeles, and Gilead Sciences, Foster City (J.M., A.O., E.S., Y.Z., D.M.B., J.G.M.) - all in California; Ludwig Maximilian University, Munich (N.G.) and Johann Wolfgang Goethe University Medical Center, Frankfurt am Main (S.Z.) - both in Germany; Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (A.M.) and Santa Maria Annunziata Hospital, Florence (F.M.) - both in Italy; University of Hong Kong (C.-L.L.) and the Chinese University of Hong Kong (H.L.Y.C.) - both in Hong Kong; Cliniques Universitaires de Bruxelles Hôpital Erasme, Université Libre de Bruxelles, Brussels (C.M.); and King's College Hospital Foundation Trust, London (K.A.).

View Article

Download full-text PDF

Source
http://www.natap.org/2015/AASLD/nejmoa1512610(1).pdf
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1512610
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1512610DOI Listing
December 2015

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

N Engl J Med 2015 Dec 17;373(27):2608-17. Epub 2015 Nov 17.

From Queen Mary University of London (G.R.F.), University College London (W.R.), King's College Hospital (W.R.), and Institute of Liver Studies (K.A.) - all in London; Beth Israel Deaconess Medical Center, Boston (N.A.); Alfred Health and Monash University (S.K.R.) and St. Vincent's Hospital (A.T.), Melbourne, VIC, and Monash Health and Monash University, Clayton, VIC (S.P.) - all in Australia; James J. Peters Veterans Affairs Medical Center, Bronx (N.B.), and Icahn School of Medicine at Mount Sinai, New York (N.B.) - both in New York; Auckland Clinical Studies, Auckland (E.J.G.), and Christchurch Clinical Studies Trust and University of Otago, Christchurch (C.A.M.S.) - both in New Zealand; Texas Liver Institute, University of Texas Health Science Center, San Antonio (E.L.); Liver Institute of Virginia, Richmond (M.L.S.); University of Ottawa, Ottawa (C.C.), and Vancouver Infectious Diseases Centre, Vancouver, BC (B.C.) - both in Canada; Kaiser Permanente (W.J.T.), Ruane Medical (P.R.), and Cedars-Sinai Medical Center (T.T.T.), Los Angeles, and Gilead Sciences, Foster City (H.M., H.D.-S., L.H., J.W., J.M., A.O., D.M.B., J.G.M.) - all in California; Hôpital Saint Joseph, Marseilles (M.B.), and Service d'Hépatologie, Hôpital Beaujon, INSERM UMR 1149, Université Paris Diderot, Clichy (T.A.) - both in France; University Hospital Leipzig, Leipzig (T.B.), and Johann Wolfgang Goethe University, Frankfurt (S.Z.) - both in Germany; Santa Maria Annunziata Hospital, Florence (F.M.), and Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (A.M.) - both in Italy; Henry Ford Health System, Detroit (S.C.G.); Duke University School of Medicine, Durham, NC (K.P.); Rush University Medical Center, Chicago (N.R.); and Johns Hopkins University, Baltimore (M.S.).

View Article

Download full-text PDF

Source
http://www.natap.org/2015/AASLD/nejmoa1512610.pdf
Web Search
http://www.nejm.org/doi/abs/10.1056/NEJMoa1512612
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1512612DOI Listing
December 2015

Bradyarrhythmias Associated with Sofosbuvir Treatment.

N Engl J Med 2015 11;373(19):1888

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1505967DOI Listing
November 2015

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

N Engl J Med 2015 Aug 21;373(8):705-13. Epub 2015 Jul 21.

From Duke Clinical Research Institute, Durham, NC (S.N.); University of Ottawa, the Ottawa Hospital, Ottawa (C.C.), and Department of Hepatology, Immunodeficiency Clinic, Toronto General Hospital, University of Toronto, Toronto (D.K.W.) - both in Canada; University of Alabama at Birmingham, Birmingham (M. Saag); Emory University, Emory Healthcare, Atlanta (K.W.); Ruane Medical and Liver Health Institute (P.R.) and Kaiser Permanente Los Angeles Medical Center (W.J.T.), Los Angeles, University of California, San Francisco, San Francisco General Hospital, San Francisco (A.L.), and Gilead Sciences, Foster City (L.M.S., J.C.Y., P.G., H.D.-S., L.N., P.S.P., J.G.M.) - all in California; Weill Cornell Medical College (K.M.), Icahn School of Medicine at Mount Sinai (N.B., D.D.), New York, and James J. Peters Veterans Affairs Medical Center, Bronx (N.B.) - all in New York; Beth Israel Deaconess Medical Center (R.P.B.), Brigham and Women's Hospital and Harvard Medical School (P.E.S.), and Community Research Initiative of New England (A.E.C.) - all in Boston; University of Auckland, Auckland City Hospital, Auckland (E.G.), and Christchurch Hospital and University of Otago, Christchurch (C.A.M.S.) - both in New Zealand; University of Puerto Rico School of Medicine (J.S.-B.) and Clinical Research Puerto Rico (J.O.M.-R.) - both in San Juan; University of Miami, Miami (D.J.); University of Pennsylvania, Philadelphia (P.T.); and Johns Hopkins University School of Medicine, Baltimore (M. Sulkowski).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1501315DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892372PMC
August 2015

Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study.

Clin Gastroenterol Hepatol 2015 Apr 18;13(4):772-9.e1-3. Epub 2014 Dec 18.

Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2014.12.014DOI Listing
April 2015

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.

J Acquir Immune Defic Syndr 2015 Apr;68(5):543-9

*Fundacion de Investigacion, Santurce, Puerto Rico; †Gilead Sciences, Inc, Foster City, CA; and ‡University of Puerto Rico, San Juan, Puerto Rico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/QAI.0000000000000516DOI Listing
April 2015

Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.

Clin Gastroenterol Hepatol 2014 Dec 9;12(12):2113-20.e1-3. Epub 2014 May 9.

National Institute for Health Research Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cgh.2014.04.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225180PMC
December 2014

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

N Engl J Med 2014 May 10;370(20):1879-88. Epub 2014 Apr 10.

From the Digestive Disease Institute, Virginia Mason Medical Center, Seattle (K.V.K.); Henry Ford Health Systems, Detroit (S.C.G.); University of Pennsylvania, Philadelphia (K.R.R.); University of California Davis Medical Center, Sacramento (L.R.), University of California at San Diego Medical Center, San Diego (M.C.), Scripps Clinic, La Jolla (P.J.P.), and Gilead Sciences, Foster City (G.M.S., D.A., E.S., R.H.H., P.S.P., W.T.S., J.G.M.) - all in California; Hofstra North Shore-Long Island Jewish School of Medicine, Manhasset, NY (D.E.B.); Texas Liver Institute and University of Texas Health Science Center, San Antonio (E.L.), and Texas Clinical Research Institute, Arlington (R.G.) - both in Texas; Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News (M.L.S.), Digestive and Liver Disease Specialists, Norfolk (M.R.), and Metropolitan Liver Diseases, Fairfax (V.R.) - all in Virginia; Center for Liver Diseases, School of Medicine, University of Miami, Miami (E.S.); Quality Medical Research, Nashville (R.H.); Saint Louis University, St. Louis (A.M.D.); Duke University Medical Center, Durham (A.J.M.), and University of North Carolina, Chapel Hill (M.W.F.) - both in North Carolina; and Indianapolis Gastroenterology Research Foundation, Indianapolis (D.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1402355DOI Listing
May 2014

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

N Engl J Med 2014 May 4;370(21):1993-2001. Epub 2014 May 4.

From the Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany (S.Z.); Royal Free Hospital and University College London School of Medicine, London (G.M.D.); Tartu University Hospital, Tartu, Estonia (R.S.); Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy (A.M.); Medical University of Bialystok, Bialystok, Poland (R.F.); Gilead Sciences, Foster City, CA (R.H.H., A.I., E.S., D.M.B., W.T.S., G.M.S., J.G.M.); Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm (O.W.); Academic Medical Center, Amsterdam (H.W.R.); Medical University of Vienna, Vienna (P.F.); Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris-Est, INSERM Unité 955, Créteil, France (C.H.); and Hospital Universitario Val d'Hebron, Barcelona (R.E.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1316145DOI Listing
May 2014

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

N Engl J Med 2014 Apr 11;370(16):1483-93. Epub 2014 Apr 11.

From Beth Israel Deaconess Medical Center, Boston (N.A.); University of Pennsylvania, Philadelphia (K.R.R.); University of Florida, Gainesville (D.R.N.); Texas Liver Institute, University of Texas Health Science Center, San Antonio (E.L.), and the North Texas Research Institute, Arlington (R.G.) - both in Texas; Henry Ford Health Systems, Detroit (S.C.G.); Center for Liver Diseases, School of Medicine, University of Miami, Miami (E.S.); ID Care, Hillsborough, NJ (R.N.); Atlanta Gastroenterology Associates, Atlanta (N.G.); Quality Medical Research, Nashville (R.H.), and Gastro One, Germantown (Z.H.Y.) - both in Tennessee; Quest Clinical Research, San Francisco (J.L.), Scripps Clinic, La Jolla (P.J.P.), and Gilead Sciences, Foster City (G.M.S., Y.Z., H.D.-S., J.C.Y., P.S.P., W.T.S., J.G.M.) - all in California; Saint Louis University, St. Louis (A.M.D.); University of New Mexico, Albuquerque (S.A.); Duke University Medical Center, Durham, NC (A.J.M.); Johns Hopkins Medical Center, Baltimore (M.S.); and Indiana University School of Medicine, Indianapolis (P.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1316366DOI Listing
April 2014